Your browser does not support JavaScript or it may be disabled!
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
Get Realtime News
on your webpage

About 823 results for "cipla india"

Indian drug firms vie for Teva portfolio
Business Standard India

Indian drug firms vie for Teva portfolio

Top pharmaceutical companies from India, including Cipla, Glenmark Pharmaceuticals and Sun Pharmaceutical Industries, are exploring bids for a drug portfolio of the world's largest generic player, Teva Pharmaceutical Industries. The portfolio on ... Business Standard India, 1 week ago
Indian drug majors vie for Teva's drug portfolio Smart Investor, 1 week ago
The Rs1 trillion FDA impact on Indian pharma, 1 week ago

Buy Cipla; target of Rs 750: Firstcall Research

Firstcall Research report on Cipla Cipla Ltd laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare and is one of the largest exporters of pharmaceutical products from India and ...
 Moneycontrol.com1 week ago Glenmark, Sun Pharma, Cipla Said to Weigh Bid for Teva Portfolio  La Repubblica1 week ago Pharma companies expand focus in OTC segment  Smart Investor3 weeks ago Pharma firms expand focus on OTC segment  Agencyfaqs!3 weeks ago

Coal India, Jindal Stainless, Cipla and Glenmark to see some action today

SENSEX 25482.52 381.95 1.48% NIFTY 7766.50 34.70 0.45% Industries: Chemicals, Automobile, IT, Metal and Mining, Medical/Healthcare, Power, Metal and Mining, Metal and Mining, Petroleum/Oil & Gas Company Indian Metals & Ferro ...
 Finalaya.com1 week ago
Nikkei Asian Review

Profit jumps on sales gain in U.S., Europe

MUMBAI (NewsRise) -- Indian drugmaker Cipla posted a 44% jump in second-quarter profit after boosting sales of formulations in North America and Europe and adding a one-time revenue gain in the U.S. Consolidated net income rose to 4.31 billion ...
 Nikkei Asian Review3 weeks ago Cipla Q2 profit rises 44% to Rs431 crore, lags estimates [Mint, New Delhi]  Bloomberg3 weeks ago UPDATE 1-India's Cipla expects lower growth in second half of 2016  Reuters India3 weeks ago Cipla reports 44% rise in Q2 net profit, lags estimates  Business Today India3 weeks ago
DNA India

Cipla appoints Kidwai as independent director

New Delhi: Cipla has appointed Naina Lal Kidwai, outgoing Chairman of HSBC India, as an independent director on its board. "We will benefit immensely from her exemplary business leadership and corporate experience as Cipla evolves on its purpose ...
 Manorama Online2 weeks ago Cipla appoints Naina Lal Kidwai as Independent Director  CPhI.cn2 weeks ago Cipla ropes in Naina Lal Kidwai, outgoing CEO of HSBC as independent director  DNA India2 weeks ago Cipla to sell entire stake in Biomab; to strengthen its focus on biotech [India Infoline News Service]  Pharmacy Choice3 weeks ago
Ani News

Sensex, Nifty open flat; Ambuja Cements down, Cipla gains

Vedanta, Cipla, ICICI Bank, ONGC, BHEL, Cairn India and HCL Tech were early gainers. HUL, Sun Pharma, HDFC Bank, Wipro, Hero Motocorp, Power Grid Corp, Ambuja Cements and BPCL lost ground. The Indian rupee slipped in early trade today. It has ...
 Moneycontrol.com4 weeks ago Stocks in news: ICICI, Dr Reddy's, HCL Tech, Cipla, Nestle  Moneycontrol.com3 weeks ago Stocks in news: Just Dial, Strides, DRL, KEC, Jet, Cipla  Moneycontrol.com4 weeks ago Sensex, Nifty flat; Ambuja Cements down, Cipla gains  Moneycontrol.com4 weeks ago

Cipla Sells Stake in China's Biomab for $25 Million

Cipla, one of India's top five drugmakers, will sell its 25% stake in Biomab Holding to its parter, Biomab Brilliant Ltd., for $26 million. After the transaction, Biomab Brilliant will own 100% of the biosimilar company, which is headquartered in ...
 Financial Content3 weeks ago Biomab Brilliant to acquire remaining 25% stake in Biomab Holding from Cipla  Individual.com3 weeks ago Cipla gains on inking definitive agreement to sell its entire 25% stake in BHL  Finalaya.com3 weeks ago Cipla Sells Stake In China's For $25 Million  BioSpace3 weeks ago

India battles big pharma over cough syrup abuse, reducing supplies

Cipla stopped making the product last year; Abbott Laboratories and Pfizer have had to reduce batch sizes by up to half. Indian regulators are privately pressuring major drug firms to better police how they sell popular codeine-based cough syrups to tackle smuggling and addiction, a move that is reducing supplies of a medicine doctors say is an effective treatment.   India's Cipla stopped making the product last year owing to regulatory demands, and US-based Abbott Laboratories and ...
 Rediff.com1 month ago Battle Over Cough Syrup Between Big Pharma and Regulators  NDTV Profit1 month ago Exclusive - India battles big pharma over cough syrup abuse, reducing supplies  EuroNews1 month ago Indian Regulators Battle Big Pharma Over Cough Syrup Abuse  NDTV4 weeks ago

Cipla Medpro, Serum Institute India in agreement

To provide vaccines in South Africa Cipla's South African subsidiary Cipla Medpro has entered into an exclusive agreement with Serum Institute of India (SII) in South Africa. The partnership will enable affordable and accessible vaccines for ...
 Financial Express3 weeks ago South Africa Plugs TB Vaccine Gap  AllAfrica.com3 weeks ago Africa: South Africa Plugs TB Vaccine Gap  Africa-News.info3 weeks ago

Sell MM, SAIL; buy Cipla: Sudarshan Sukhani

Sudarshan Sukhani of recommends selling Mahindra & Mahindra and Steel Authority of India and advises buying Cipla. S udarshan Sukhani of told CNBC-TV18, "One can sell Mahindra & Mahindra and Steel Authority of ...
 Moneycontrol.com4 weeks ago
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts


Realtime News

on your Webpage

Add Widget >Get your members hooked!
Get updated on latest news & your favorite topics right in your inbox!
More     Less